Positive outcomes in Gram-positive infections
19 April 2008, 16.30-18.30
Integrated symposium arranged by Novartis Pharma AG. The opinion of the speakers is not necessarily congruent with that of ESCMID.
- Chairpersons: José M. Miró (Barcelona, ES), John Segreti (Chicago, US)
Welcome and introduction, Issues in achieving positive outcomes in Gram-positive infections - José M. Miró (Barcelona, ES)
Empiric or targeted therapy: getting it right from the start - John Segreti (Chicago, US)
Which antibiotic for which patient? - Review of clinical outcomes by patient type - George Sakoulas (Valhalla, US)
Future treatment options for Gram-positive infections - Looking ahead - Alasdair MacGowan (Bristol, UK)
Maximizing positive outcomes for Gram-positive infections - Jean-Paul Stahl (Grenoble, FR)
Questions and answers
Antifungal therapy: a practical approach to improving outcomes
20 April 2009, 9.00-11.00
Integrated symposium arranged by Schering-Plough. The opinion of the speakers is not necessarily congruent with that of ESCMID.
- Chairpersons: Juan Luis Rodriguez-Tudela (Madrid, ES), Cornelia Lass-Flörl (Innsbruck, AT)
Programme overview and opening comments - Juan Luis Rodriguez-Tudela (Madrid, ES)
Emerging trends in the epidemiology of invasive fungal infections - Cornelia Lass-Flörl (Innsbruck, AT)
The role of diagnostics in managing invasive fungal infections - Paul Verweij (Nijmegen, NL)
The evidence for antifungal prophylaxis in clinical practice - Thierry Calandra (Lausanne, CH)
Tailoring antifungal therapy according to new trends - Dimitrios Kontoyiannis (Houston, US)
Panel discussion - Cornelia Lass-Flörl (Innsbruck, AT)
Concluding remarks
MRSA: The changing epidemiology of the epidemic
20 April 2008, 9.00-11.00
Integrated symposium arranged by Pfizer. The opinion of the speakers is not necessarily congruent with that of ESCMID.
- Chairpersons: Gary French (London, UK), Evelina Tacconelli (Rome, IT)
- Introduction and overview
- Gary French (London, UK)
Epidemiology and resistance mechanisms of methicillin-resistant Staphylococcus aureus - Georg Peters (Munster, DE)
Case-based presentations
Barriers to managing patients with MRSA in 2008 - Robert G Sawyer (Charlottesville, US)
Therapeutic strategies for MRSA - Pramod M Shah (Frankfurt, DE)
Challenges in the management of patients with nosocomial pneumonial infections - Jean Chastre (Paris, FR)
Panel questions and answers
Concluding remarks
Management of fungal infection in the ICU setting
20 April 2008, 16.00-18.00
Integrated symposium arranged by Pfizer. The opinion of the speakers is not necessarily congruent with that of ESCMID.
- Chairpersons: Bart-Jan Kullberg (Nijmegen, NL), Philippe-Eggimann (Lausanne, CH)
- Introduction and overview
- Bart-Jan Kullberg (Nijmegen, NL)
Diagnosis and prognosis - First line treatment options - Peter Gaustad (Oslo, NO)
Clinical significance of Candida colonization in ICU patients - Paolo Manzoni (Turin, IT)
Case-based presentations
Quantifying the risk for invasive Candida infections in 2008 - Therapeutic strategies and challenges - Georg Maschmeyer (Potsdam, DE)
Challenges in managing patients with Candida and other fungal infection - Daniel Kett (Miami, US)
Panel questions and answers
Concluding remarks
Treating community-acquired pneumonia: is there room for improvement?
20 April 2008, 16.00-18.00
Integrated symposium arranged by Bayer Schering Pharma. The opinion of the speakers is not necessarily congruent with that of ESCMID.
- Chairpersons: Roger Finch (Nottingham, UK), Hartmut Lode (Berlin, DE)
- Introduction
- Roger Finch (Nottingham, UK)
Incidence of CAP - are we having an impact? - Keith Paul Klugman (Atlanta, US)
Is the aetiology of CAP changing? - Donald Low (Toronto, CA)
Do we follow 'best practice' guidelines when treating CAP? - Torsten Bauer (Berlin, DE)
Making the best use of available therapy in CAP - Hartmut Lode (Berlin, DE)
Summary and close
Update in severe communtiy-acquired pneumonia: mortality, mechanisms and medical intervention
21 April 2008, 16.00-18.00
Integrated symposium arranged by Novartis Pharma AG. The opinion of the speakers is not necessarily congruent with that of ESCMID.
- Chairpersons: Steven Opal (Providence, US), Pierre-Francois Laterre (Brussels, BE)
Welcome, introductions and objectives
Epidemiology, guidelines, processes of care and clinical experience in severe communtiy-acquired pneumonia - Jordi Rello (Tarragona, ES)
Infection as an initiation of coagulation and inflammation: targeting the lung - Tom ver der Poll (Amsterdam, NL)
Rationale and the role of biologic adjunctive therapy in sCAP - Pierre-Francois Laterre (Brussels, BE)
The role of biomarkers - predicting patients at risk of decompensation and responders to adjunctive therapy - Jeal-Paul Mira (Paris, FR)
Panel discussion
Closing remarks
